Clinical Trial Update: Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update shows that switching to raltegravir provides sustained virological suppression and improves adverse events in people living with H…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Raltegravir (raltegravir)

Snippet

Sponsor: Lin, Hsi-Hsun, M.D. | Conditions: HIV Infection, Adverse Drug Reaction | Phase 4 | Status: COMPLETED